Ultrastructural effects of oritavancin on methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus.
The ultrastructural effects of the lipoglycopeptide oritavancin on methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococcus (VRE) were examined by transmission electron microscopy. Oritavancin but not vancomycin induced aberrant septum formation and loss of staining of nascent septal cross walls in MRSA. Septal distortions were also observed in VRE exposed to oritavancin.
Belley
Adam
A
Targanta Therapeutics Inc., St. Laurent, Quebec, Canada.
Harris
Robert
R
Beveridge
Terry
T
Parr
Tom
T
Moeck
Gregory
G
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001426:Bacterial Proteins / Q000235:genetics / Q000378:metabolism; D015169:Colony Count, Microbial; D020285:Cryoelectron Microscopy; D016983:Enterococcus / Q000187:drug effects* / Q000648:ultrastructure*; D006020:Glycopeptides / Q000494:pharmacology*; D000077427:Lipoglycopeptides; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects* / Q000648:ultrastructure*; D014640:Vancomycin / Q000494:pharmacology / Q000031:analogs & derivatives; D020713:Vancomycin Resistance / Q000187:drug effects*
D000900:Anti-Bacterial Agents; D001426:Bacterial Proteins; D006020:Glycopeptides; D000077427:Lipoglycopeptides; C079913:VanB protein, Enterococcus; D014640:Vancomycin; C100708:oritavancin